Literature DB >> 9634207

HIV-associated brain pathology: a comparative international study.

J Davies1, I P Everall, S Weich, J Glass, L R Sharer, E S Cho, J E Bell, C Majteny, F Gray, F Scaravilli, P L Lantos.   

Abstract

Little is known about the frequency and variation of HIV-associated brain pathology in different geographical centres. To assess whether there is an association between the frequency of disease and demographic factors we examined the neuropathological findings in four European and two American cities. The cities included London, Edinburgh, Paris, Budapest, Baltimore and Newark. Information was collected on a total of 1144 cases. HIV encephalitis was the most common observation in all the centres. although its frequency varied between them (P < 0.01). Furthermore, there were significant differences (P < 0.001) between the various categories of exposure and the frequency of HIV encephalitis in Edinburgh and other centres. The occurrence of toxoplasmosis, progressive multifocal leukoencephalolpathy (PML) and cryptococcal infection also differed between the various centres (P < 0.01). None of the findings was attributable to age, sex, or ethnic origin, but the introduction of anti-retroviral treatment, such as Zidovudine, may have been important. Overall, this study highlights geographical variability and the potential importance for group of exposure and anti-retroviral medication as factors affecting the development of various HIV-associated brain lesions.

Entities:  

Mesh:

Year:  1998        PMID: 9634207     DOI: 10.1046/j.1365-2990.1998.00096.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  9 in total

Review 1.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

2.  Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.

Authors:  Jijin Gu; Karam Al-Bayati; Emmanuel A Ho
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 3.  Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS.

Authors:  Jonathan Pitcher; Saori Shimizu; Silvia Burbassi; Olimpia Meucci
Journal:  J Neuroimmunol       Date:  2010-06-08       Impact factor: 3.478

Review 4.  Regulation of neuronal ferritin heavy chain, a new player in opiate-induced chemokine dysfunction.

Authors:  Anna Cook Abt; Olimpia Meucci
Journal:  J Neuroimmune Pharmacol       Date:  2011-04-05       Impact factor: 4.147

Review 5.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

6.  Spectrum of intracranial parenchymal lesions in patients with human immunodeficiency virus infection in the Republic of Korea.

Authors:  Pyoeng Gyun Choe; Wan Beom Park; Jin Su Song; Kyoung-Ho Song; Jae Hyun Jeon; Sang-Won Park; Hong Bin Kim; Kee-Hyun Chang; Myoung-don Oh; Kang Won Choe; Nam Joong Kim
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

Review 7.  Neurobiology of multiple insults: HIV-1-associated brain disorders in those who use illicit drugs.

Authors:  Jeanne E Bell; Juan-Carlos Arango; Iain C Anthony
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-05       Impact factor: 4.147

8.  Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity.

Authors:  Kimberley A Walsh; Joseph F Megyesi; John X Wilson; Jeff Crukley; Victor E Laubach; Robert R Hammond
Journal:  J Neuroinflammation       Date:  2004-05-27       Impact factor: 8.322

9.  Attenuated SIV causes persisting neuroinflammation in the absence of a chronic viral load and neurotoxic antiretroviral therapy.

Authors:  Deborah Ferguson; Sean Clarke; Neil Berry; Neil Almond
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.